2. Signaling Pathways
  3. Immunology/Inflammation
  4. Tim3

Tim3

T-Cell Immunoglobulin and Mucin Containing Protein-3; CD366

Tim3 is an immunoglobulin type protein expressed exclusively on the surface of differentiated Th1 cells. It is a co-inhibitory receptor immune checkpoint protein that regulates macrophage activation, and inhibits Th1-mediated auto- and alloimmune responses, and promotes immunological tolerance.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-163028
    ML-T7
    		99.93%
    ML-T7 is a potent Tim-3 inhibitor. ML-T7 blocks Tim-3 interactions with PtdSer and CEACAM1. ML-T7 not only enhances the antitumor activity of adoptive transfer therapy with cytotoxic T lymphocytes (CTLs) and CAR T cells but also increases the effector function of T cell. ML-T7 promotes NK cells’ killing activity against tumor cells and DC antigen-presenting capacity. ML-T7 directly exerts antitumor efficacy in preclinical tumor models either alone or in combination with Nivolumab (HY-P9903A). ML-T7 can be used for tumor immunotherapy research.
    ML-T7
  • HY-P99044
    Sabatolimab
    		99.15%
    Sabatolimab (MBG453) is a high-affinity, humanized, IgG4 (S228P) antibody targeting TIM-3, an inhibitory receptor that regulates adaptive and innate immune responses. Sabatolimab is a potential immunosuppression agent that can target TIM-3 on immune and myeloid cells.
    Sabatolimab
  • HY-P99827
    Cobolimab
    		Inhibitor 98.00%
    Cobolimab (TSR-022) is an anti-TIM-3 monoclonal antibody. Cobolimab mediates the internalization of TIM3 with an IC50 value of 0.4464 nM. Cobolimab has potential application in solid tumors and non-small cell lung cancer (NSCLC).
    Cobolimab
  • HY-155175
    TIM-3-IN-2
    		Inhibitor 99.44%
    TIM-3-IN-2 is a TIM-3 inhibitor. TIM-3-IN-2 blocks the interactions of TIM-3 with PtdSer, CEACAM1 and Gal-9, and inhibits the immunosuppressive function of TIM-3. TIM-3-IN-2 restores IFNγ release from peripheral blood mononuclear cells. TIM-3-IN-2 inhibits the proliferation of acute myeloid leukemia cells. TIM-3-IN-2 can be used for the research of acute myeloid leukemia.
    TIM-3-IN-2
  • HY-N2907
    Atranorin
    		Inhibitor 99.68%
    Atranorin is a secondary metabolite of lichens and AKT inhibitor. Atranorin possesses multiple activities such as antibacterial, anti-inflammatory, antioxidant, anti-glycation, analgesic, and anti-tumor effects. Atranorin has IC50 values for scavenging DPPH and ABTS free radicals of 117 μM and less than 10 μM, respectively. Additionally, Atranorin also exhibits effects in promoting wound healing. Atranorin can be used in the research of various diseases, including myelodysplastic syndromes, tumors, and inflammatory conditions.
    Atranorin
  • HY-P992342
    DCB-8
    		Inhibitor
    DCB-8 is a specific inhibitor targeting human TIM-3. DCB-8 regulates T cell function, enhances cytokine secretion, and inhibits tumor growth in disease animal models. DCB-8 can be used for cancer research.
    DCB-8
  • HY-P992460
    SHR-1702
    		Inhibitor
    SHR-1702 is a monoclonal antibody targeting TIM-3, which specifically binds to and blocks the TIM-3 signaling pathway. SHR-1702 restores the function of immune cells and inhibits the proliferation process of malignant cells. SHR-1702 is mainly used in relevant research on acute myeloid leukemia and myelodysplastic syndromes.
    SHR-1702
  • HY-P992398
    LBL-003
    		Inhibitor
    LBL-003 is a fully human monoclonal antibody targeting TIM-3. LBL-003 can be used for cancer research.
    LBL-003
  • HY-P990004
    Anti-Mouse TIM-3 Antibody (B8.2C12)
    		Inhibitor 99.48%
    Anti-Mouse TIM-3 Antibody (B8.2C12) is an anti-mouse TIM-3 IgG1 monoclonal antibody. Anti-Mouse TIM-3 Antibody (B8.2C12) can block the binding of Tim-3 with Phosphatidylserine (PtdSer) and CEACAM1 without interfering with the binding to Galectin-9. Anti-Mouse TIM-3 Antibody (B8.2C12) can inhibit tumor growth and activate tumor infiltrating CD8+ T cells. Anti-Mouse TIM-3 Antibody (B8.2C12) can be used for studying cancer such as breast cancer and colon cancer and constructing experimental autoimmune encephalomyelitis (EAE) models.
    Anti-Mouse TIM-3 Antibody (B8.2C12)
  • HY-P990821
    Anti-Mouse TIM-3 Antibody (RMT3-23)
    		Inhibitor 99.64%
    Anti-Mouse TIM-3 Antibody (RMT3-23) is a kind of rat-derived anti-mouse TIM-3 IgG2a antibody inhibitor. Anti-Mouse TIM-3 Antibody (RMT3-23) blocks Tim-3 binding to phosphatidylserine (PtdSer) and carcinoembryonic antigen cell adhesion molecule 1 (CEACAM1). Anti-Mouse TIM-3 Antibody (RMT3-23) inhibits phagocytosis of apoptotic cells in peritoneal exudate Mac1+ cells. Anti-Mouse TIM-3 Antibody (RMT3-23) can be used for the researches of inflammation and immunology, such as rheumatoid arthritis.
    Anti-Mouse TIM-3 Antibody (RMT3-23)
  • HY-144987
    RBN013209
    		Inhibitor 98.63%
    RBN013209 is an orally active small molecule inhibitor of CD38 with an IC50 of 0.01 to 0.1 μM for human CD38. RBN013209 prevents the conversion of extracellular NAD+ to ADPR or cADPR in tumor cells and PBMCs. RBN013209 can be used in the study of tumor. In addition, RBN013209 enables CAR-T cells to maintain the naive state and central memory state, and decreases the expression of cell activation markers and exhaustion-related inhibitory receptors.
    RBN013209
  • HY-P991449
    LY3415244
    		Inhibitor
    LY3415244 is a human bispecific antibody (bsAb) targeting B7-H1/PD-L1/CD274 & TIM-3/HAVCR2/CD366. LY3415244 can be used in advanced solid tumors research.
    LY3415244
  • HY-159884
    MG-T-19
    		Inhibitor 98.34%
    MG-T-19 is an effective TIM-3 inhibitor that can suppress the interaction of TIM-3 with PtdSer, CEACAM1, and Gal-9. MG-T-19 can increase the production of tumor necrosis factor-α (TNF-α) and interferon-γ (IFN-γ) in peripheral blood mononuclear cells (PBMCs) from healthy donors, and enhance the ability of PBMCs to inhibit the proliferation of Kasumi-1 cells (an acute myelogenous leukemia cell line).
    MG-T-19
  • HY-139738
    TIM-3-IN-1
    		98.90%
    TIM-3-IN-1 (Compound 38) is a TIM-3 inhibitor that can be used for the research of cancer.
    TIM-3-IN-1
  • HY-P990085
    Verzistobart
    		Inhibitor 99.9%
    Verzistobart is an IgG1κ antibody targeting the hepatitis A virus cellular receptor HAVCR2.
    Verzistobart
  • HY-P991198
    M6903
    		Ligand 98.81%
    M6903 is a humanized monoclonal IgG2 antibody targeting T cell immunoglobulin and mucin domain-3 (TIM-3) (KD for human TIM-3 is 2.3 nM). M6903 binds to TIM-3, blocking the binding of TIM-3 to phosphatidylserine (PtdSer), carcinoembryonic antigen cell adhesion-related molecule 1 (CEACAM1), and galectin 9 (Gal-9), thus relieving TIM-3-mediated T cell inhibition and exerting the activities of activating antigen-specific T cells and enhancing anti-tumor immunity. M6903 is promising for research of cancers.
    M6903
  • HY-P990716
    Sabestomig
    		Inhibitor 98.33%
    Sabestomig (AZD7789) is a monovalent bispecific antibody targeting PD-1 and TIM-3. Sabestomig binds to PD-1 and an epitope in the TIM-3 IgV domain outside the phosphatidylserine-binding cleft, thereby precisely regulating immune responses. Sabestomig promotes IL-2 production, efferocytosis and cross-presentation of tumor antigens, and enhances the release of anti-tumor T cell cytokines, cytotoxicity, and secretion of IFN-γ. Sabestomig inhibits the growth of solid tumors, prolongs the duration of tumor suppression, and significantly enhances anti-tumor responses following anti-PD-1 therapy. Sabestomig has been used in studies related to non-small cell lung cancer and classical Hodgkin lymphoma.
    Sabestomig
  • HY-P991396
    LY-3321367
    		Inhibitor 99.0%
    LY-3321367 is a human monoclonal antibody (mAb) targeting TIM-3/HAVCR2/CD366. LY-3321367 can be used in solid tumors research.
    LY-3321367
  • HY-N2907R
    Atranorin (Standard)
    		Inhibitor
    Atranorin (Standard) is the analytical standard of Atranorin (HY-N2907). This product is intended for research and analytical applications. Atranorin is a secondary metabolite of lichens and AKT inhibitor. Atranorin possesses multiple activities such as antibacterial, anti-inflammatory, antioxidant, anti-glycation, analgesic, and anti-tumor effects. Atranorin has IC50 values for scavenging DPPH and ABTS free radicals of 117 μM and less than 10 μM, respectively. Additionally, Atranorin also exhibits effects in promoting wound healing. Atranorin can be used in the research of various diseases, including myelodysplastic syndromes, tumors, and inflammatory conditions.
    Atranorin (Standard)
  • HY-P991397
    Sym023
    		Inhibitor
    Sym023 is a human monoclonal antibody (mAb) targeting TIM-3/HAVCR2/CD366. Sym023 enhances immunostimulatory and anti-tumor activities. Sym023 can be used in Non-small cell lung cancer, Solid tumors and Lymphoma research.
    Sym023
Cat. No. Product Name / Synonyms Application Reactivity